首页> 美国卫生研究院文献>Journal of Visualized Experiments : JoVE >Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
【2h】

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

机译:基于新型原子力显微镜的生物淘选分离肌萎缩性侧索硬化症中针对TDP-43变体的形态学特异性试剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Because protein variants play critical roles in many diseases including TDP-43 in Amyotrophic Lateral Sclerosis (ALS), alpha-synuclein in Parkinson’s disease and beta-amyloid and tau in Alzheimer’s disease, it is critically important to develop morphology specific reagents that can selectively target these disease-specific protein variants to study the role of these variants in disease pathology and for potential diagnostic and therapeutic applications. We have developed novel atomic force microscopy (AFM) based biopanning techniques that enable isolation of reagents that selectively recognize disease-specific protein variants. There are two key phases involved in the process, the negative and positive panning phases. During the negative panning phase, phages that are reactive to off-target antigens are eliminated through multiple rounds of subtractive panning utilizing a series of carefully selected off-target antigens. A key feature in the negative panning phase is utilizing AFM imaging to monitor the process and confirm that all undesired phage particles are removed. For the positive panning phase, the target antigen of interest is fixed on a mica surface and bound phages are eluted and screened to identify phages that selectively bind the target antigen. The target protein variant does not need to be purified providing the appropriate negative panning controls have been used. Even target protein variants that are only present at very low concentrations in complex biological material can be utilized in the positive panning step. Through application of this technology, we acquired antibodies to protein variants of TDP-43 that are selectively found in human ALS brain tissue. We expect that this protocol should be applicable to generating reagents that selectively bind protein variants present in a wide variety of different biological processes and diseases.
机译:由于蛋白质变体在许多疾病中都起着关键作用,包括肌萎缩性侧索硬化症(ALS)中的TDP-43,帕金森氏病中的α-突触核蛋白以及阿尔茨海默氏病中的β-淀粉样蛋白和tau,因此开发可选择性靶向的形态学特异性试剂至关重要这些特定疾病的蛋白质变异体,以研究这些变异体在疾病病理学中的作用以及潜在的诊断和治疗应用。我们已经开发出了基于原子力显微镜(AFM)的新型生物淘选技术,该技术能够分离能够选择性识别疾病特异性蛋白质变体的试剂。该过程涉及两个关键阶段,负向和平移阶段。在阴性淘选阶段,通过使用一系列精心选择的脱靶抗原进行多轮减性淘选,消除了对脱靶抗原具有反应性的噬菌体。负淘选阶段的关键功能是利用AFM成像监控过程并确认已清除所有不需要的噬菌体颗粒。对于正淘选阶段,将目标靶抗原固定在云母表面上,洗脱并筛选结合的噬菌体,以鉴定能选择性结合靶抗原的噬菌体。如果已经使用了合适的阴性淘选对照,则不需要纯化靶蛋白变体。甚至在复杂的生物材料中仅以非常低的浓度存在的靶蛋白变体也可以用于阳性淘选步骤。通过应用该技术,我们获得了针对在人ALS脑组织中选择性发现的TDP-43蛋白变体的抗体。我们希望该协议适用于生成与多种不同生物学过程和疾病中存在的蛋白质变异体选择性结合的试剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号